Targeting the ErbB3/ErbB2 pathway with neutralizing antibodies seribantumab (MM-121) and pertuzumab counteracted the protective effects of CAF and improved melanoma cell drug responsiveness [431]. The gene discussed is ERBB3; the disease is melanoma.